Skip to main content
Caris Life Sciences, Inc. (CAI)
NASDAQ: CAI · Real-Time Price · USD
28.00
+7.00 (33.33%)
At close: Jun 18, 2025, 4:00 PM
28.50
+0.50 (1.79%)
Pre-market: Jun 20, 2025, 6:17 AM EDT

Caris Life Sciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
 TTM FY 2024 FY 2023 FY 2022
Period Ending
 Mar '25 Dec '24 Dec '23 Dec '22
Revenue
452.5412.26306.13258.49
Revenue Growth (YoY)
-34.67%18.43%-
Cost of Revenue
241.42231.83214.87178.46
Gross Profit
211.08180.4391.2680.02
Selling, General & Admin
334.04326.05296.04294.51
Research & Development
99.89111.5114.77101.27
Operating Expenses
433.93437.55410.81395.78
Operating Income
-222.85-257.12-319.55-315.76
Interest Expense
-53.52-50.03-31.61-26.68
Interest & Investment Income
5.867.1211.260.95
Other Non Operating Income (Expenses)
-2.9418.149.420.66
EBT Excluding Unusual Items
-273.44-281.89-330.5-320.83
Other Unusual Items
---10.92-
Pretax Income
-273.44-281.89-341.42-320.83
Net Income
-273.44-281.89-341.42-320.83
Preferred Dividends & Other Adjustments
97.7296.37121.1179
Net Income to Common
-371.16-378.26-462.53-399.83
Shares Outstanding (Basic)
142142140133
Shares Outstanding (Diluted)
142142140133
Shares Change (YoY)
-1.58%4.73%-
EPS (Basic)
-2.61-2.66-3.31-3.00
EPS (Diluted)
-2.61-2.66-3.31-3.00
Free Cash Flow
-212.01-253.64-298.42-327.96
Free Cash Flow Per Share
-1.49-1.79-2.13-2.46
Gross Margin
46.65%43.77%29.81%30.96%
Operating Margin
-49.25%-62.37%-104.38%-122.16%
Profit Margin
-82.02%-91.75%-151.09%-154.68%
Free Cash Flow Margin
-46.85%-61.52%-97.48%-126.88%
EBITDA
-184.6-208.21-270.55-267.5
EBITDA Margin
-40.79%-50.50%-88.38%-103.49%
D&A For EBITDA
38.2548.914948.25
EBIT
-222.85-257.12-319.55-315.76
EBIT Margin
-49.25%-62.37%-104.38%-122.16%
Revenue as Reported
452.5412.26306.13258.49
Advertising Expenses
-1.261
Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q